TY - JOUR
T1 - Relationships between nitric oxide biomarkers and physiological outcomes following dietary nitrate supplementation
AU - Wei, Chenguang
AU - Vanhatalo, Anni
AU - Black, Matthew I.
AU - Rajaram, Raghini
AU - Kadach, Stefan
AU - Jones, Andrew M.
AU - Blackwell, James
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/7/1
Y1 - 2024/7/1
N2 - Dietary nitrate (NO3−) supplementation can increase nitric oxide (NO) bioavailability, reduce blood pressure (BP) and improve muscle contractile function in humans. Plasma nitrite concentration (plasma [NO2−]) is the most oft-used biomarker of NO bioavailability. However, it is unclear which of several NO biomarkers (NO3−, NO2−, S-nitrosothiols (RSNOs)) in plasma, whole blood (WB), red blood cells (RBC) and skeletal muscle correlate with the physiological effects of acute and chronic dietary NO3− supplementation. Using a randomized, double-blind, crossover design, 12 participants (9 males) consumed NO3−-rich beetroot juice (BR) (∼12.8 mmol NO3−) and NO3−-depleted placebo beetroot juice (PL) acutely and then chronically (for two weeks). Biological samples were collected, resting BP was assessed, and 10 maximal voluntary isometric contractions of the knee extensors were performed at 2.5–3.5 h following supplement ingestion on day 1 and day 14. Diastolic BP was significantly lower in BR (−2 ± 3 mmHg, P = 0.03) compared to PL following acute supplementation, while the absolute rate of torque development (RTD) was significantly greater in BR at 0–30 ms (39 ± 57 N m s−1, P = 0.03) and 0–50 ms (79 ± 99 N m s−1, P = 0.02) compared to PL following two weeks supplementation. Greater WB [RSNOs] rather than plasma [NO2−] was correlated with lower diastolic BP (r = −0.68, P = 0.02) in BR compared to PL following acute supplementation, while greater skeletal muscle [NO3−] was correlated with greater RTD at 0–30 ms (r = 0.64, P=0.03) in BR compared to PL following chronic supplementation. We conclude that [RSNOs] in blood, and [NO3−] in skeletal muscle, are relevant biomarkers of NO bioavailability which are related to the reduction of BP and the enhanced muscle contractile function following dietary NO3− ingestion in humans.
AB - Dietary nitrate (NO3−) supplementation can increase nitric oxide (NO) bioavailability, reduce blood pressure (BP) and improve muscle contractile function in humans. Plasma nitrite concentration (plasma [NO2−]) is the most oft-used biomarker of NO bioavailability. However, it is unclear which of several NO biomarkers (NO3−, NO2−, S-nitrosothiols (RSNOs)) in plasma, whole blood (WB), red blood cells (RBC) and skeletal muscle correlate with the physiological effects of acute and chronic dietary NO3− supplementation. Using a randomized, double-blind, crossover design, 12 participants (9 males) consumed NO3−-rich beetroot juice (BR) (∼12.8 mmol NO3−) and NO3−-depleted placebo beetroot juice (PL) acutely and then chronically (for two weeks). Biological samples were collected, resting BP was assessed, and 10 maximal voluntary isometric contractions of the knee extensors were performed at 2.5–3.5 h following supplement ingestion on day 1 and day 14. Diastolic BP was significantly lower in BR (−2 ± 3 mmHg, P = 0.03) compared to PL following acute supplementation, while the absolute rate of torque development (RTD) was significantly greater in BR at 0–30 ms (39 ± 57 N m s−1, P = 0.03) and 0–50 ms (79 ± 99 N m s−1, P = 0.02) compared to PL following two weeks supplementation. Greater WB [RSNOs] rather than plasma [NO2−] was correlated with lower diastolic BP (r = −0.68, P = 0.02) in BR compared to PL following acute supplementation, while greater skeletal muscle [NO3−] was correlated with greater RTD at 0–30 ms (r = 0.64, P=0.03) in BR compared to PL following chronic supplementation. We conclude that [RSNOs] in blood, and [NO3−] in skeletal muscle, are relevant biomarkers of NO bioavailability which are related to the reduction of BP and the enhanced muscle contractile function following dietary NO3− ingestion in humans.
KW - Nitric oxide biomarkers
KW - Rate of torque development
KW - S-nitrosothiols
KW - Skeletal muscle
UR - http://www.scopus.com/inward/record.url?scp=85192305020&partnerID=8YFLogxK
U2 - 10.1016/j.niox.2024.04.010
DO - 10.1016/j.niox.2024.04.010
M3 - Article
C2 - 38697467
AN - SCOPUS:85192305020
SN - 1089-8603
VL - 148
SP - 23
EP - 33
JO - Nitric Oxide - Biology and Chemistry
JF - Nitric Oxide - Biology and Chemistry
ER -